Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Anti-BCMA CAR-T cells |
| Trade Name | |
| Synonyms | CART-BCMA|CT053 |
| Drug Descriptions |
Anti-BCMA CAR-T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting BCMA, which may enhance antitumor immune response (PMID: 23344265). |
| DrugClasses | TNFRSF17 Immune Cell Therapy 27 |
| CAS Registry Number | NA |
| NCIT ID | C156272 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Anti-BCMA CAR-T cells | Anti-BCMA CAR-T cells | 0 | 3 |
| Anti-BCMA CAR-T cells + Cyclophosphamide + Fludarabine | Anti-BCMA CAR-T cells Cyclophosphamide Fludarabine | 0 | 2 |
| Anti-BCMA CAR-T cells + Cyclophosphamide + Fludarabine + LY3039478 | Anti-BCMA CAR-T cells Cyclophosphamide Fludarabine LY3039478 | 0 | 1 |
| Anti-BCMA CAR-T cells + NT-I7 | Anti-BCMA CAR-T cells NT-I7 | 0 | 1 |